Oleg Movchan Sells 11,452 Shares of Enfusion, Inc. (NYSE:ENFN) Stock

Enfusion, Inc. (NYSE:ENFN - Get Free Report) CEO Oleg Movchan sold 11,452 shares of Enfusion stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $11.39, for a total value of $130,438.28. Following the sale, the chief executive officer now directly owns 631,847 shares of the company's stock, valued at $7,196,737.33. This represents a 1.78 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Oleg Movchan also recently made the following trade(s):

• On Monday, March 3rd, Oleg Movchan sold 2,790 shares of Enfusion stock. The stock was sold at an average price of $11.48, for a total transaction of $32,029.20.
• On Tuesday, January 7th, Oleg Movchan sold 2,771 shares of Enfusion stock. The shares were sold at an average price of $10.13, for a total value of $28,070.23.

Enfusion Stock Up 0.3 %

ENFN stock traded up $0.04 during trading on Tuesday, hitting $11.15. 780,007 shares of the company's stock traded hands, compared to its average volume of 1,156,687. The firm has a market capitalization of $1.44 billion, a P/E ratio of 278.69, a PEG ratio of 1.85 and a beta of 0.95. Enfusion, Inc. has a 1 year low of $7.83 and a 1 year high of $11.80. The business has a fifty day simple moving average of $10.99 and a two-hundred day simple moving average of $9.92.

Enfusion (NYSE:ENFN - Get Free Report) last issued its quarterly earnings results on Monday, March 3rd. The company reported $0.01 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.03 by ($0.02). The company had revenue of $52.94 million for the quarter, compared to analyst estimates of $53.98 million. Enfusion had a net margin of 1.70% and a return on equity of 6.67%. On average, equities research analysts predict that Enfusion, Inc. will post 0.06 EPS for the current fiscal year.

Remove Ads

Institutional Investors Weigh In On Enfusion

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ENFN. KLP Kapitalforvaltning AS acquired a new position in shares of Enfusion in the fourth quarter valued at approximately $75,000. Harbor Capital Advisors Inc. grew its stake in Enfusion by 12.4% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 11,887 shares of the company's stock worth $113,000 after buying an additional 1,315 shares during the last quarter. Millennium Management LLC purchased a new stake in Enfusion in the 4th quarter valued at $114,000. Dark Forest Capital Management LP acquired a new position in Enfusion in the 4th quarter valued at about $128,000. Finally, Man Group plc purchased a new stake in shares of Enfusion during the fourth quarter worth approximately $131,000. Institutional investors and hedge funds own 81.05% of the company's stock.

Analyst Ratings Changes

A number of brokerages have recently weighed in on ENFN. William Blair reiterated a "market perform" rating on shares of Enfusion in a research report on Monday, January 13th. Stifel Nicolaus boosted their target price on Enfusion from $11.00 to $13.00 and gave the stock a "buy" rating in a report on Wednesday, December 18th. Finally, Piper Sandler lifted their price objective on Enfusion from $10.00 to $11.50 and gave the stock a "neutral" rating in a report on Monday, December 23rd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $11.13.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.